The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
This section includes select Daiichi Sankyo-sponsored congress presentationsExplore congresses
This section includes select Daiichi Sankyo-sponsored publications.Explore Publications
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects
Tachibana M, Matsuki S, Maekawa Y, et al.
Clin Transl Sci. 2023. doi: 10.1111/cts.13613. Online ahead of print.
Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial
Goto K, Goto Y, Kubo T, et al.
J Clin Oncol. 2023;JCO2301361. doi: 10.1200/JCO.23.01361. Online ahead of print.
HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy
Yu HA, Goto Y, Hayashi H, et al.
J Clin Oncol. 2023;JCO2301476. doi: 10.1200/JCO.23.01476. Online ahead of print.